CymaBay Therapeutics to Present at Two Investor Conferences

NEWARK, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference, and the LEERINK Partners Roundtable Series:  Rare Disease & Immuno-Oncology conference.

About CymaBay CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional information about CymaBay visit www.cymabay.com.

Contact:
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
[email protected]

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]

You May Also Be Interested In

• Corpay (CPAY) PT Raised to $480 at Cantor Fitzgerald
• COSCIENS Biopharma Inc. Reports Q2 2026 Results
• Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador